Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jacqueline Wubben is active.

Publication


Featured researches published by Jacqueline Wubben.


Vaccine | 2000

High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules.

Lbachir BenMohamed; Alan W. Thomas; Marc Bossus; Karima Brahimi; Jacqueline Wubben; Pierre Druilhe

We have investigated the immunogenicity in chimpanzees of twelve synthetic peptides derived from four new Plasmodium falciparum molecules expressed at pre-erythrocytic stages of the human malaria parasite. These parasite molecules were initially selected through their ability to be recognized by stage restricted human antibodies. Twelve 20- to 41-mer peptides representing potential human B- or T-cell epitopes were selected from these proteins, and synthesized. Six of these were modified by a C-terminal lipidic chain in order to re-inforce their immunogenicity. Strong B- and T-helper cell responses were induced in chimpanzees by lipopeptides injected without adjuvant and by peptides in Montanide. All twelve peptides induced CD4(+) T-cell proliferative responses, as well as the secretion of IFN-gamma (some of them at very high levels) and eleven peptides induced antibody responses. The immune responses elicited in this way were reactive with native parasite proteins, as shown by recall studies with sporozoite stage proteins, and proved to be long-lasting (up to 10 months after immunization). Our results support the strategy employed to select these four new malarial antigens and the corresponding peptides, and suggest that the immunizing formulations are both efficient and clinically acceptable.


Journal of Immunology | 2004

Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF-β1+CD4+ T Regulatory Cell Infiltrates

Jose Torrealba; Masaaki Katayama; John H. Fechner; Ewa Jankowska-Gan; Satoshi Kusaka; Qingyong Xu; Jacqueline M. Schultz; Terry D. Oberley; Huaizhong Hu; Majed M. Hamawy; Margreet Jonker; Jacqueline Wubben; Gaby G. M. Doxiadis; Ronald E. Bontrop; William J. Burlingham; Stuart J. Knechtle

Approaches that prevent acute rejection of renal transplants in a rhesus monkey model were studied to determine a common mechanism of acceptance. After withdrawal of immunosuppression, all 14 monkeys retained normal allograft function for >6 mo. Of these, nine rejected their renal allograft during the study, and five maintained normal function throughout the study period. The appearance of TGF-β1+ interstitial mononuclear cells in the graft coincided with a nonrejection histology, whereas the absence/disappearance of these cells was observed with the onset of rejection. Analysis with a variety of TGF-β1-reactive Abs indicated that the tolerance-associated infiltrates expressed the large latent complex form of TGF-β1. Peripheral leukocytes from rejecting monkeys lacking TGF-β1+ allograft infiltrates responded strongly to donor Ags in delayed-type hypersensitivity trans-vivo assays. In contrast, allograft acceptors with TGF-β1+ infiltrates demonstrated a much weaker peripheral delayed-type hypersensitivity response to donor alloantigens (p < 0.01 vs rejectors), which could be restored by Abs that either neutralized active TGF-β1 or blocked its conversion from latent to active form. Anti-IL-10 Abs had no restorative effect. Accepted allografts had CD8+ and CD4+ interstitial T cell infiltrates, but only the CD4+ subset included cells costaining for TGF-β1. Our data support the hypothesis that the recruitment of CD4+ T regulatory cells to the allograft interstitium is a final common pathway for metastable renal transplant tolerance in a non-human primate model.


European Journal of Immunology | 2012

Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant.

S. Anwar Jagessar; Nicole Heijmans; Erwin L. A. Blezer; Jan Bauer; Jeroen H. Blokhuis; Jacqueline Wubben; Jan W. Drijfhout; Peter J. van den Elsen; Jon D. Laman; Bert A. 't Hart

Induction of experimental autoimmune encephalomyelitis (EAE) has been documented in common marmosets using peptide 34–56 from human myelin/oligodendrocyte glycoprotein (MOG34‐56) in incomplete Freunds adjuvant (IFA). Here, we report that this EAE model is associated with widespread demyelination of grey and white matter. We performed an in‐depth analysis of the specificity, MHC restriction and functions of the activated T cells in the model, which likely cause EAE in an autoantibody‐independent manner. T‐cell lines isolated from blood and lymphoid organs of animals immunized with MOG34–56 displayed high production of IL‐17A and specific lysis of MOG34–56‐pulsed EBV B‐lymphoblastoid cells as typical hallmarks. Cytotoxicity was directed at the epitope MOG40–48 presented by the non‐classical MHC class Ib allele Caja‐E, which is orthologue to HLA‐E and is expressed in non‐inflamed brain. In vivo activated T cells identified by flow cytometry in cultures with MOG34–56, comprised CD4+CD56+ and CD4+CD8+CD56+ T cells. Furthermore, phenotypical analysis showed that CD4+CD8+CD56+ T cells also expressed CD27, but CD16, CD45RO, CD28 and CCR7 were absent. These results show that, in the MOG34–56/IFA marmoset EAE model, a Caja‐E‐restricted population of autoreactive cytotoxic T cells plays a key role in the process of demyelination in the grey and white matter.


Transplantation | 2005

The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppression dependent.

Margreet Jonker; Anna J. Danskine; Krista G. Haanstra; Jacqueline Wubben; Ivanela Kondova; Eva-Maria Kuhn; Marlene L. Rose

Background. Chronic allograft nephropathy (CAN) is a common late complication of kidney transplantation. Antibodies to both human leukocyte antigen and nonhuman leukocyte antigen antigens have been implicated in the development of this condition. Here we investigated the presence of antivimentin antibodies in nonhuman primate recipients of kidney allografts as a possible predictor of CAN and the effects of immunosuppression. Methods. Thirty seven rhesus monkeys received a kidney allograft to study the potency of several different immunosuppressive regimens (conventional immunosuppression, n=19, vs. costimulatory blockade, n=18). Monkeys were tested for antivimentin antibody by enzyme-linked immunosorbent assay and for anti-donor antibody by staining donor spleen cells with recipient serum. The appearance of antibodies was correlated with the graft pathology in biopsy and necropsy material. Results. Antivimentin antibodies were found in 31 of 37 animals, whereas only 15 of 32 animals made anti-donor antibodies. Conventional immunosuppression did not prevent antivimentin antibody formation. Costimulation blockade, in particular blocking CD40 and CD86, significantly delayed or prevented antivimentin antibody formation, but did not prevent CAN. Antivimentin antibodies were not significantly associated with development of CAN. Conclusions. We postulate that vimentin acts as an autoantigen after renal transplantation; it elicits an autoimmune response that is not regulated by cyclosporine. This autoimmune response may be part of the complex immunologic events occurring posttransplantation and may contribute to the development of CAN, but cannot be considered as a major cause of CAN because this condition also develops without antivimentin antibodies.


Transplantation | 2003

T-cell-specific immunosuppression results in more than 53 days survival of porcine islets of langerhans in the monkey.

Josephine K. R. A. Rijkelijkhuizen; Krista G. Haanstra; Jacqueline Wubben; Annemiek T ns; Anja Roos; Dani lle J. van Gijlswijk-Janssen; Jan Ringers; E. Bouwman; Margreet Jonker

Background. Transplantation of islets of Langerhans can restore insulin production in diabetic patients. Because of the shortage of human donor organs, transplantation of porcine islets may be an alternative solution. The present study was aimed at the characterization of rejection mechanisms of porcine islets transplanted into eight nondiabetic monkeys under the kidney capsule. Methods. Cultured adult pig islets were used, which showed no expression of the galactose(&agr;1,3)galactose epitope, major histocompatibility complex class II, or CD45, and no binding of antibodies or complement after exposure to monkey serum. Immunosuppression consisted of cyclophosphamide, cyclosporine A (CsA), and steroids (group 1); or antithymocyte globulin, anti–interleukin-2 receptor antibody, CsA, and steroids (group 2). In three animals of group 2, islets were also transplanted in the portal vein. Results. Although all monkeys had preformed anti-pig antibodies, no correlation was found between antibody titers and rejection and no deposition of antibodies or complement was observed in the grafts. Group 1 showed islets up to day 11, followed by T-cell infiltration and rejection at approximately day 14. In group 2, two monkeys showed infiltrates consisting predominantly of T cells starting at approximately day 29, whereas two monkeys showed well-preserved islets without infiltration up to day 53. In the livers of the three monkeys that also received islets intraportally and were resectioned on days 21, 33, and 49, no islets could be detected. Conclusions. This study demonstrates that cultured adult pig islets can survive in the monkey for more than 53 days without signs of rejection under standard immunosuppression.


American Journal of Transplantation | 2007

Expression Patterns of Regulatory T-Cell Markers in Accepted and Rejected Nonhuman Primate Kidney Allografts

Krista G. Haanstra; Jacqueline Wubben; Sander S. Korevaar; Ivanela Kondova; Carla C. Baan; Margreet Jonker

The identification of FOXP3 expressing cells in recipients of an allograft, in particular inside the graft itself, may help to define criteria for immunosuppressive drug withdrawal. We therefore examined expression patterns of several regulatory T‐cell (Treg) markers in kidney biopsies and kidney tissues taken at the time of graft rejection from monkeys treated with αCD40, αCD86, CsA, a combination of these or after drug withdrawal.


Transplantation | 2002

Long-term kidney graft survival by delayed T cell ablative treatment in rhesus monkeys.

Margreet Jonker; Jan Ringers; Miriam Ossevoort; Wim Slingerland; Yvon Van Den Hout; Krista G. Haanstra; Jacqueline Wubben; Eva M. Kuhn; Peter J. Friend; Roy Calne

BACKGROUND Tolerance to organ allografts in primates including man has been elusive, although in rodents and pigs tolerance can be achieved to organ allografts with relatively short courses of immunosuppressive treatment. In all varieties of graft acceptance that do not require full-dose maintenance immunosuppression, immunological engagement of donor and recipient and an early unstable period have been observed. On the basis of the hypothesis that elimination of aggressive T cell function should tip the balance in favor of an operationally tolerant state, experiments have been performed in monkeys allowing recipient-donor interaction before T-cell ablation and a short course of immunosuppression. METHODS Rhesus monkeys received an allogeneic kidney graft from a MHC-mismatched donor. The animals either received anti-CD3 immunotoxin (FN18-CRM9) alone, started 2 days after transplantation, or in combination with a short course of cyclosporine (CsA) and/or rapamycin (RAPA), started at 5 days after transplantation. Kidney function was followed by monitoring serum creatinine levels and regular biopsies. Humoral and cellular antidonor immunity was tested in vitro before and at several time points after transplantation. RESULTS Graft survival of monkeys that received CsA alone (mean survival time (MST)=29.3) was significantly prolonged compared with the controls (MST=6). FN18-CRM9 treatment alone also resulted in prolonged graft survival (MST=29.4). The combined treatment of FN18-CRM9 and CsA and/or RAPA resulted in prolonged graft survival after all immunosuppression was stopped (MST=207.8). CONCLUSIONS It seems feasible to postpone immunosuppression posttransplantation and yet prevent allograft rejection without the need of permanent immunosuppression.


Transplantation | 2006

No synergy between ATG induction and costimulation blockade induced kidney allograft survival in rhesus monkeys

Krista G. Haanstra; Ella A. Sick; Jan Ringers; Jacqueline Wubben; Eva-Maria Kuhn; Bert A. 't Hart; Louis Boon; Margreet Jonker

Background. Costimulation blockade with antibodies directed against human CD40 and CD86 leads to prolonged kidney allograft survival in rhesus monkeys, but fails to induce permanent graft acceptance. We have tested whether costimulation blockade is more effective after peripheral T-cell ablation with antithymocyte globulin (ATG), with the aim to remove already primed autoreactive cells present in the normal repertoire. Methods. Rhesus monkeys were transplanted with a mismatched kidney allograft. ATG was given around the time of transplantation (day −1 and 0). Costimulation blockade with anti-CD40+anti-CD86 was given at tapering dosages from day −1 to 56. Cyclosporin A (CsA) was given from day 42 onwards and first rejections occurring after day 42 were treated with prednisone. Results. We observed accelerated rejection in ATG-treated monkeys, compared to animals receiving only costimulation blockade. The accelerated rejection of the kidney allograft occurred despite the application of rejection therapy with steroids and CsA. Three of the five ATG-treated animals were found seropositive for donor-specific alloantibodies. Early biopsies (day 21) from animals treated with ATG and anti-CD40+anti-CD86 show substantially reduced expression of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and forkhead box P3 (FOXP3) in focal infiltrates as compared to animals treated with only costimulation blockade. Furthermore, we observed the rapid reappearance of CD8+ T-cells with a memory phenotype (disappearance of naive CD95low/CD11alow T-cells) in peripheral blood. Conclusion. We conclude that (subtotal) T-cell depletion using ATG does not add to costimulation blockade induced kidney allograft survival.


Transplantation | 2002

Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates

Jan Ringers; Krista G. Haanstra; Richard A. Kroczek; Katrin Kliem; Eva M. Kuhn; Jacqueline Wubben; Miriam Ossevoort; H.-D. Volk; Margreet Jonker

Background. In rodents it has been demonstrated that blockade of the CD40-CD154 (CD40L) pathway at the time of donor-specific blood transfusion (DST) can result in indefinite graft survival. Because it has been reported in the past that DST in monkeys can have a favorable effect on graft outcome and that blockade of the CD40-CD154 pathway can lead to prolonged kidney graft survival in monkeys, we have combined anti-CD154 treatment with DST in a monkey kidney graft model. The aim of this study was to investigate the immunosuppressive potential of blocking the CD40-CD154 interaction at the time of a DST in rhesus monkeys. Methods. One donor-derived blood transfusion was given on day −15 after the first anti-CD154 injection. The anti-CD154 antibody was given on days −15, −13, −11, −9, and −7. The kidney was transplanted on day 0. Cyclosporine was given after kidney trans-plantation. Results. No major difference in graft survival was observed between the groups. The animals died due to grade II acute rejection. At the time of transplantation, no antibody response could be detected directed against donor antigens. After transplantation, all animals surviving for more than 3 weeks had antidonor antibodies. There were no differences in the intragraft events analyzed by real time reverse transcriptase-polymerase chain reaction. Conclusions. DST under the cover of relatively high levels of anti-CD154 failed to result in prolonged graft survival or prevent the formation of antidonor antibodies, when cyclosporine was given after transplantation.


PLOS ONE | 2013

Induction of encephalitis in rhesus monkeys infused with lymphocryptovirus-infected B-cells presenting MOG(34-56) peptide.

Krista G. Haanstra; Jacqueline Wubben; Margreet Jonker; Bert A. 't Hart

The overlapping epidemiology of multiple sclerosis (MS) and Epstein-Barr virus (EBV), the increased risk to develop MS after infectious mononucleosis (IM) and the localization of EBV-infected B-cells within the MS brain suggest a causal link between EBV and MS. However, the underlying mechanism is unknown. We hypothesize that EBV-infected B-cells are capable of eliciting a central nervous system (CNS) targeting autoimmune reaction. To test this hypothesis we have developed a novel experimental model in rhesus monkeys of IM-like disease induced by infusing autologous B-lymphoblastoid cells (B-LCL). Herpesvirus papio (HVP) is a lymphocryptovirus related to EBV and was used to generate rhesus monkey B-LCL. Three groups of five animals were included; each group received three intravenous infusions of B-LCL that were either pulsed with the encephalitogenic self peptide MOG34–56 (group A), a mimicry peptide (981–1003) of the major capsid protein of cytomegalovirus (CMVmcp981–1003; group B) or the citrullinated MOG34–56 (cMOG34–56; group C). Groups A and B received on day 98 a single immunization with MOG34–56 in incomplete Freund’s adjuvant (IFA). Group C monkeys were euthanized just prior to day 98 without booster immunization. We observed self-peptide-specific proliferation of T-cells, superimposed on similar strong proliferation of CD3+CD8+ T-cells against the B-LCL as observed in IM. The brains of several monkeys contained perivascular inflammatory lesions of variable size, comprising CD3+ and CD68+ cells. Moreover, clusters of CD3+ and CD20+ cells were detected in the meninges. The only evident clinical sign was substantial loss of bodyweight (>15%), a symptom observed both in early autoimmune encephalitis and IM. In conclusion, this model suggests that EBV-induced B-LCL can elicit a CNS targeting inflammatory (auto)immune reaction.

Collaboration


Dive into the Jacqueline Wubben's collaboration.

Top Co-Authors

Avatar

Margreet Jonker

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Krista G. Haanstra

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Bert A. 't Hart

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Jan Ringers

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Eva-Maria Kuhn

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Ingrid H.C.H.M. Philippens

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Ivanela Kondova

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar

Alan W. Thomas

Biomedical Primate Research Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eva M. Kuhn

Biomedical Primate Research Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge